AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$PRCT

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

PROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developin

Original reporting
SEC EDGAR 8-K
Published Nov 4, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PRCT
Neutral
high confidence
Mentioned
$PRCT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PRCTNeutralMed
01

Why it matters

The reaffirmed guidance indicates management confidence in meeting its growth targets, but the increased loss may temper investor enthusiasm.

02

Market read

The earnings release provides fresh data for traders; the reaffirmed guidance suggests limited immediate price movement but offers a basis for positioning ahead of the full‑year results.

03

What to watch

The upcoming WATER IV trial results in early 2027 could materially affect future valuation but are not reflected in current guidance.

Relevance 7/10Novelty 8/10Timing: after‑hours release today

Background

PROCEPT BioRobotics is a surgical robotics company focused on urology, reporting its third quarter 2026 financials via an SEC Form 8‑K.

Company-level read

Ticker impact

$PRCTNeutralHigh confidence
Context

PROCEPT BioRobotics (Nasdaq: PRCT) reported Q3 2026 results and reaffirmed full‑year 2026 revenue and EBITDA guidance.

Expected impact

likely modest pressure as the market prices in the reaffirmed guidance and higher loss.

Evidence & confidence

The earnings release provides fresh numbers and confirms guidance, giving traders a clear view of performance and outlook without new upside or downside surprises.

Market effects

Sector

Urology robotics sector sees continued growth; peers may be evaluated against PROCEPT's revenue expansion and margin profile.

Regional

Limited to U.S. healthcare and medical device investors.

Global

Minimal global impact; primarily relevant to US-listed biotech/medical device investors.

Counterpoint

What could challenge this read

Despite higher revenue, the widening loss and unchanged guidance could signal underlying cost pressures, suggesting a potential short opportunity if margins deteriorate.

Key entities

  • Executive
    Larry Wood

    Chief Executive Officer of PROCEPT BioRobotics, quoted in the release.

Read at source← All news

Related articles

$PRCTMed

PROCEPT BioRobotics Q3 Earnings Call Highlights

PROCEPT BioRobotics reported Q3 revenue of $98.3M, up 19% YoY. U.S. revenue rose 16% to $85.8M, while international revenue climbed 32% to $12.5M. Gross margin improved to 66%. The company maintained its 2026 revenue forecast of $390M-$410M and expects adjusted EBITDA loss of $30M-$35M for the year. PROCEPT also discussed 2027 growth expectations and clinical trials for prostate cancer treatments.

finance.yahoo.com
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com